Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection - PubMed (original) (raw)

Observational Study

Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection

Chandrasekar Gopalakrishnan et al. JAMA Intern Med. 2020.

Abstract

Importance: Previous observational studies have suggested that fluoroquinolones are associated with aortic aneurysm or dissection, but these studies may be subject to confounding by indication or surveillance bias.

Objective: To assess the association of fluoroquinolones with risk of aortic aneurysm or aortic dissection (AA/AD) while accounting for potential confounding by fluoroquinolone indication and bias owing to differential surveillance.

Design, setting, and participants: In an observational cohort study using a US commercial claims database, 2 pairwise 1:1 propensity score-matched cohorts were identified: patients aged 50 years or older with a diagnosis of pneumonia 3 days or less before initiating treatment with a fluoroquinolone or azithromycin and patients aged 50 years or older with a urinary tract infection (UTI) diagnosis 3 days or less before initiating a fluoroquinolone or combined trimethoprim and sulfamethoxazole. Hazard ratios (HRs) and 95% CIs were estimated controlling for 85 baseline confounders. In a secondary analysis, patients receiving fluoroquinolones were compared with those receiving amoxicillin, both with and without considering baseline aortic imaging, to address differences in detection of AA/AD before antibiotic use. Data on patients within the database from January 1, 2003, through September 30, 2015, were analyzed. Data analysis was conducted from July 23, 2019, to July 6, 2020.

Main outcomes and measures: Hospitalization for AA/AD occurring within 60 days following treatment initiation.

Results: After propensity score matching, patient characteristics were well balanced, with 279 554 patients (mean [SD] age, 63.66 [10.93] years; 149 976 women [53.6%]) in the pneumonia cohort and 948 364 patients (mean [SD] age, 62.06 [10.33] years; 823 667 women [86.9%]) in the UTI cohort. Initiators of fluoroquinolones (n = 139 772 pairs in the pneumonia cohort and n = 474 182 pairs in the UTI cohort) had an increased rate of AA/AD compared with initiators of azithromycin (HR, 2.57; 95% CI, 1.36-4.86; incidence, 0.03% for fluoroquinolones vs 0.01% for azithromycin) but no increased rate compared with initiators of combined trimethoprim and sulfamethoxazole (HR, 0.99; 95% CI, 0.62-1.57; incidence, <0.01% in both UTI groups). Secondary analysis using amoxicillin as a comparator (n = 3 976 162 pairs) produced results consistent with those from earlier studies (HR, 1.54; 95% CI, 1.33-1.79; incidence, <0.01% in both groups). Requiring baseline imaging in this cohort (n = 542 649 pairs) to address surveillance bias attenuated the increased rate (HR, 1.13; 95% CI, 0.96-1.33; incidence, 0.06% for fluoroquinolones vs 0.05% for amoxicillin).

Conclusions and relevance: The findings of this nationwide cohort study of adults with pneumonia or UTI suggest an increased relative rate of AA/AD associated with fluoroquinolones within the pneumonia cohort but not within the UTI cohort. In both cohorts, the absolute rate of AA/AD appeared to be low (<0.1%). The increased relative rate observed in the pneumonia cohort may be due to residual confounding or surveillance bias.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Bykov reported receiving consulting fees from Alosa Health for unrelated work. Dr Fischer reported receiving consulting fees from Alosa Health for unrelated work. Dr Gagne reported receiving grants from Eli Lilly and Company and Novartis Pharmaceuticals Corp and personal fees from Optum Inc outside the submitted work. No other disclosures were reported.

Figures

Comment in

Similar articles

Cited by

References

    1. Heidelbaugh JJ, Holmstrom H. The perils of prescribing fluoroquinolones. J Fam Pract. 2013;62(4):191-197. - PubMed
    1. Olesen SW, MacFadden D, Grad YH. Cumulative probability of receiving an antibiotic prescription over time. N Engl J Med. 2019;380(19):1872-1873. doi:10.1056/NEJMc1816699 - DOI - PMC - PubMed
    1. Kabbani S, Hersh AL, Shapiro DJ, Fleming-Dutra KE, Pavia AT, Hicks LA. Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits. Clin Infect Dis. 2018;67(1):134-136. doi:10.1093/cid/ciy035 - DOI - PMC - PubMed
    1. MacFadden DR, Ridgway JP, Robicsek A, Elligsen M, Daneman N. Predictive utility of prior positive urine cultures. Clin Infect Dis. 2014;59(9):1265-1271. doi:10.1093/cid/ciu588 - DOI - PubMed
    1. Lee C-C, Lee MG, Hsieh R, et al. . Oral fluoroquinolones and the risk of aortic dissection. J Am Coll Cardiol. 2018;72(12):1369-1378. doi:10.1016/j.jacc.2018.06.067 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources